written on 10.02.2014

Merck collaborates with Samsung to develop copy of Sanofi's Lantus diabetes therapy


Lantus is insulin glargine, a longer-acting product than regular insulin. Merck is hoping to bring MK-1293, its own insulin glargine treatment, to market with the help of its biosimilar drug partner. Phase III studies will begin soon, Merck said.